Neil John Press

This inventor holds 14 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Novartis Ag. Active years: 2006-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Neil John Press. Retrieved from https://idiyas.com/inventor/neil-john-press

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 4)

% Patents Active = 35.7

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 64(Granted Patents)

Location History:

West Sussex, GB (2007 - 2012)
Horsham, GB (2006 - 2015)

Company Filing History:

14 out of 3,978

Novartis Ag

patents

Years Active: 2006-2015

Loading Chart...

Areas of Expertise:

CXCR2 Antagonist

PDE4 Inhibitor

Muscarinic Receptor

Squaramide Derivatives

Quaternary Ammonium Salts

Adenosine Receptor

Pyrrolidinium Derivatives

Quinoline-2-one Derivatives

Naphthyridine Derivatives

Amino-thiazoles

Quinuclidine Derivatives

CXC-Chemokine Receptor

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9115087 - Squaramide derivatives as CXCR2 antagonist (2015-08-25),

2. 8722925 - Squaramide derivatives as CXCR2 antagonist (2014-05-13),

3. 8383625 - Pyrrolidinium derivatives as M3 muscarnic receptor antagonists (2013-02-26),

4. 8329754 - Squaramide derivatives as CXCR2 antagonist (2012-12-11),

5. 8288588 - Squaramide derivatives as CXCR2 antagonist (2012-10-16),

6. 8183281 - CXC-chemokine receptor ligands (2012-05-22),

7. 8153669 - Quaternary ammonium salts as M3 antagonists (2012-04-10),

8. 8084463 - Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists (2011-12-27),

9. 7989497 - Squaramide derivatives as CXCR2 antagonist (2011-08-02),

10. 7745462 - Quinoline-2-one derivatives for the treatment of airways diseases (2010-06-29),

11. 7723356 - Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists (2010-05-25),

12. 7468370 - [1,7]naphthyridines as PDE4 inhibitors (2008-12-23),

13. 7273875 - Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (PDE4) inhibitors (2007-09-25),

14. 7109202 - Aminothaizoles and their use as adenosine receptor antagonists (2006-09-19),

Title: The Innovative Journey of Neil John Press

Introduction: Neil John Press, a pioneering inventor hailing from Horsham, GB, has made significant contributions to the world of innovations with his creative mind and dedication to progress.

Latest Patents: Neil John Press has recently been granted patents for cutting-edge technologies in the field of renewable energy and sustainable agriculture, showcasing his commitment to addressing pressing global challenges.

Career Highlights: Throughout his illustrious career, Neil John Press has been at the forefront of groundbreaking inventions, with a focus on enhancing efficiency and sustainability. His inventions have revolutionized various industries, earning him recognition as a visionary inventor.

Collaborations: Neil John Press has collaborated with leading research institutions and innovative companies to bring his ideas to life. His partnerships have been instrumental in turning his concepts into tangible solutions that have a positive impact on society.

Conclusion: Neil John Press's passion for innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of inventors. His remarkable contributions continue to inspire future generations to push the boundaries of what is possible in the realm of inventions.

Profile summary based on public USPTO records.